



CAMSING HEALTHCARE LIMITED

(Company Registration No. 197903888Z)
(Incorporated in the Republic of Singapore)

CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED 30 APRIL 2022

Note:

Pursuant to a notice of compliance issued by Singapore Exchange Regulation dated 6 February 2020, Camsing Healthcare Limited is required, under Rule 705(2C) of the Mainboard Rules of the Singapore Exchange Securities Trading Limited, to perform quarterly reporting of financial results with effect from third quarter of 2021.

Please refer to the reasons and circumstances leading to the delayed release of this set of financial results announcement for the three months and financial year ended 31 January 2022 as set out in our unaudited financial results for the full year ended 31 January 2019 (“FY2019”) released via SGXNET on 4 December 2021.

CAMSING HEALTHCARE LIMITED

Contents

	Page
Condensed Interim Consolidated Statements Comprehensive Income	3
Condensed Interim Statements of Financial Position	4
Condensed Interim Statements of Changes in Equity	6
Condensed Interim Consolidated Statements of Cash Flows	8
Notes to the Condensed Interim Financial Statements	9
Other Information Required by Listing Rules Appendix 7.2	20

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED 30 APRIL 2022**

		3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000	Change % +/-
	Note			
Revenue	5	1,327	1,346	(1%)
Cost of sales		(571)	(632)	(10%)
Gross Profit		<u>756</u>	<u>714</u>	6%
Other income		36	315	(89%)
Marketing and distribution costs		(919)	(1,007)	(9%)
Administrative and other operating expenses		(199)	(280)	(29%)
Finance costs		(73)	(24)	204%
Loss Before Tax	7	(399)	(282)	41%
Income tax expense		<u>-</u>	<u>-</u>	-
Loss for the Period		<u>(399)</u>	<u>(282)</u>	41%
Other Comprehensive Income/(Loss):				
Items that may be reclassified subsequently to profit or loss				
Exchange difference on translation of foreign operations		<u>-</u>	<u>-</u>	-
Other Comprehensive Income/(Loss), Net of Tax		<u>-</u>	<u>-</u>	-
Total Comprehensive Loss for the Period		<u>(399)</u>	<u>(282)</u>	41%
Loss Attributable to:				
Owners of the Company		(399)	(282)	41%
Non-controlling interest		<u>-</u>	<u>-</u>	-
		<u>(399)</u>	<u>(282)</u>	41%
Total Comprehensive Loss Attributable to:				
Owners of the Company		(399)	(282)	41%
Non-controlling interest		<u>-</u>	<u>-</u>	-
		<u>(399)</u>	<u>(282)</u>	41%

N.M.: Not Meaningful

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
AS AT 30 APRIL 2022**

	Note	Group		Company	
		30 Apr 2022 S\$'000	31 Jan 2022 S\$'000	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000
ASSETS					
Non-Current Assets					
Property, plant and equipment	11	102	106	-	-
Right-of-use assets	12	1,979	1,616	-	-
Investment in subsidiaries		-	-	900	900
Other receivables	14	289	244	-	-
		<u>2,370</u>	<u>1,966</u>	<u>900</u>	<u>900</u>
Current Assets					
Inventories	13	640	618	-	-
Trade receivables	14	148	93	-	-
Other receivables	14	827	322	1,613	61
Current tax asset		30	39	-	-
Cash and cash equivalents		557	474	233	-
		<u>2,202</u>	<u>1,546</u>	<u>1,846</u>	<u>61</u>
TOTAL ASSETS		<u>4,572</u>	<u>3,512</u>	<u>2,746</u>	<u>961</u>
Current Liabilities					
Trade payables	16	709	746	-	-
Other payables	16	1,696	2,119	450	877
Contract liabilities	5	338	177	-	-
Provisions		45	45	-	-
Lease liabilities	17	1,182	1,126	-	-
Loans and borrowings	15	744	864	-	-
		<u>4,714</u>	<u>5,077</u>	<u>450</u>	<u>877</u>
Non-Current Liabilities					
Other payables	16	2,289	716	2,289	-
Lease liabilities	17	1,122	888	-	-
Provisions		180	165	-	-
		<u>3,591</u>	<u>1,769</u>	<u>2,289</u>	<u>-</u>
TOTAL LIABILITIES		<u>8,305</u>	<u>6,846</u>	<u>2,739</u>	<u>877</u>
NET (LIABILITIES)/ ASSETS		<u>(3,733)</u>	<u>(3,334)</u>	<u>7</u>	<u>84</u>

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION
AS AT 30 APRIL 2022 (cont'd)**

	Note	Group		Company	
		30 Apr 2022 S\$'000	31 Jan 2022 S\$'000	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000
EQUITY					
Capital and Reserves					
Attributable to Equity					
Holders of the					
Company					
Share capital	18	14,250	14,250	14,250	14,250
Foreign currency translation deficit		(4)	(4)	-	-
Accumulated losses		(17,976)	(17,577)	(14,243)	(14,166)
Equity attributable to owners of the Company		(3,730)	(3,331)	7	84
Non-controlling interests		(3)	(3)	-	-
NET (DEFICIT)/ EQUITY		(3,733)	(3,334)	7	84

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED 30 APRIL 2022**

Group	Share Capital S\$'000	Foreign Currency Translation Reserve S\$'000	Accumulated Losses S\$'000	Equity Attributable to Owners of the Company S\$'000	Non- Controlling Interest S\$'000	Total S\$'000
Balance at 1 February 2022	14,250	(4)	(17,577)	(3,331)	(3)	(3,334)
Loss for the period, representing total comprehensive loss for the period	-	-	(399)	(399)	-	(399)
Balance at 30 April 2022	14,250	(4)	(17,976)	(3,730)	(3)	(3,733)
Balance at 1 February 2021	14,250	(19)	(16,249)	(2,018)	(2)	(2,020)
Loss for the period, representing total comprehensive loss for the period	-	-	(282)	(282)	-	(282)
Balance at 30 April 2021	14,250	(19)	(16,531)	(2,300)	(2)	(2,302)

CAMSING HEALTHCARE LIMITED**CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED 30 APRIL 2022 (cont'd)**

Company	Share Capital S\$'000	Accumulated Losses S\$'000	Total S\$'000
Balance at 1 February 2022	14,250	(14,166)	84
Loss for the period, representing total comprehensive loss for the period	-	(77)	(77)
Balance at 30 April 2022	<u>14,250</u>	<u>(14,243)</u>	<u>7</u>
Balance at 1 February 2021	14,250	(13,779)	471
Loss for the period, representing total comprehensive loss for the period	-	(126)	(126)
Balance at 30 April 2021	<u>14,250</u>	<u>(13,905)</u>	<u>345</u>

CAMSING HEALTHCARE LIMITED

**CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED 30 APRIL 2022**

	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000
Operating Activities:		
Loss Before Tax	(399)	(282)
Adjustments For:		
Depreciation for property, plant and equipment	20	29
Depreciation for right-of-use assets	289	328
Property, plant and equipment written off	-	5
Gain on lease modification	-	(250)
Interest expense	73	24
Rent concessions and rebate	-	(10)
Operating Cash Flows before Changes in Working Capital	<u>(17)</u>	<u>(156)</u>
Trade and other receivables	(596)	476
Inventories	(22)	(36)
Trade and other payables	(464)	200
Contract liabilities	161	-
Provisions	15	(26)
Cash (Used in)/Generated from Operations	<u>(923)</u>	<u>458</u>
Income tax paid	-	(39)
Net Cash Flows (Used in)/ from Operating Activities	<u>(923)</u>	<u>419</u>
Investing Activities:		
Purchase of property, plant and equipment	(16)	(30)
Net Cash Flows Used in Investing Activities	<u>(16)</u>	<u>(30)</u>
Financing Activities:		
Loan from Investor	1,532	-
Repayment of loans and borrowings	(120)	(121)
Repayment of lease liabilities	(362)	(505)
Interest paid	(28)	(24)
Net Cash Flows from / (Used in) Financing Activities	<u>1,022</u>	<u>(650)</u>
Net increase/(decrease) in cash and bank balances	83	(261)
Cash and bank balances at beginning of financial period	474	735
Cash and Bank Balances at End of Financial Period	<u>557</u>	<u>474</u>

CAMSING HEALTHCARE LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

1 GENERAL INFORMATION

Camsing Healthcare Limited (the “Company” and together with its subsidiaries, the “Group”) is a limited liability company domiciled and incorporated in Singapore and is listed on the Singapore Exchange Securities Trading Limited (the “SGX-ST”). The address of the Company's registered office is at 24 Raffles Place #20-03 Clifford Centre, Singapore 048621. The address of its principal place of business is 10 Kaki Bukit Ave 1 #04-05 Kaki Bukit Industrial Park Singapore 417942. The principal activity of the Company is that of investment holding. The principal activity of its principal subsidiary, Nature’s Farm Pte Ltd (“NF”), is trading in health foods and supplements.

2 BASIS OF PREPARATION

The condensed interim financial statements for the three months ended 30 April 2022 are prepared in accordance with the historical cost convention, except as disclosed in the accounting policies below and are drawn up in accordance with the Singapore Financial Reporting Standards (International) (“SFRS(I)”) – 34 *Interim Financial Reporting*. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the change in the Group’s financial position and performance of the Group since the last annual financial statements for the financial year ended 31 January 2022. The financial statements are presented in Singapore dollars (“S\$”) and all values are rounded to the nearest thousand (S\$’000) as indicated.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I), except for the adoption of new and revised standards as set out below.

2.1 Adoption of New and Revised Standards

In the current financial period, the Group has adopted the new and revised SFRS(I) and Interpretations of SFRS(I) (“SFRS(I) INT”) that are relevant to its operations and effective for the current financial period. Changes to the Group’s accounting policies have been made as required, in accordance with the transitional provisions in the respective SFRS(I) and SFRS(I) INT. The adoption of these new and revised SFRS(I) and SFRS(I) INT did not result in substantial changes to the Group’s and Company’s accounting policies and had no material effect on the financial results or position.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

2 BASIS OF PREPARATION (cont'd)

2.2 Fundamental Accounting Concept

The Group incurred a net loss of S\$399,000 (30 April 2021: S\$282,000) for the financial period ended 30 April 2022. As at 30 April 2022, the Group had bank borrowings and cash and bank balances which amounted to approximately S\$744,000 and S\$557,000 (31 January 2022: S\$864,000 and S\$474,000) respectively as well as a net equity deficit of S\$3,733,000 (31 January 2022: S\$3,334,000).

As disclosed in Note 10 of the financial statements for the financial year ended 31 January 2022, the Group has breached certain bank covenants and defaulted on the repayment of bank loans since 31 January 2019. By a letter of demand dated 27 August 2019, the bank demanded repayment of bank borrowings (including accrued interest thereon and other charges) owing by the Group. Subsequently, the Group fully repaid one of the outstanding bank loans amounting to S\$316,000 by September 2021 and managed to seek the agreement of the bank to restructure the repayment of the remaining balance. As at date of this report, the Group still owes the bank a remaining loan balance of approximately S\$648,000.

The facts and circumstances above indicate the existence of material uncertainties that may cast significant doubts over the ability of the Group and the Company to continue as a going concern. Notwithstanding this, the accompanying financial statements have been prepared on a going concern basis on the following grounds:

- (i) In May 2021, the Group obtained an unsecured loan of S\$300,000 from its ultimate holding company and the loan was extended to November 2022.
- (ii) In October 2021, the Group obtained an unsecured working capital loan of S\$300,000 from an independent party (the "Investor") who has expressed interest in investing in the Company. In December 2021 and February 2022, the Investor extended further working capital loans of S\$400,000, and S\$600,000 respectively to the Group. Such working capital loans have since been formalised in a loan agreement dated 25 December 2021.
- (iii) In December 2021, the Company entered into an investment agreement and a loan agreement ("First Loan Agreement") with the Investor wherein the Investor would be extending and injecting substantial sums of funds to the Company subject to the satisfaction of certain conditions as stipulated in the agreements.
- (iv) As announced via SGXNet on 3 March 2022, the Company entered, among others, a second loan agreement ("Second Loan Agreement") with the Investor. Pursuant to and subject to the terms and conditions of the Second Loan Agreement, the Investor shall loan to the Company up to an aggregate principal amount of S\$2.99 million for purchase of healthcare supplements and other operational or working capital purposes. As of the date of the Announcement, the Company has received approximately S\$1.9 million from the Investor pursuant to the Second Loan Agreement.
- (v) The ultimate holding company has given its undertaking to provide additional financing to the Group as and when the latter requires.
- (vi) The Group would generate sufficient cash flows in the next 12 months to enable it to continue as a going concern.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

3 CRITICAL ACCOUNTING ESTIMATES, ASSUMPTIONS AND JUDGEMENTS

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 January 2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

4 SEASONAL OPERATIONS

The Group's businesses were not affected significantly by seasonal or cyclical factors during the financial period.

5 REVENUE

(i) Disaggregation of revenue from contracts with customers

The Company derives revenue from contracts with customers through the transfer of goods at a point in time and these pertain to retail revenue derived in Singapore.

	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000
Sales of health foods and supplements	1,294	1,321
Consignment income	33	25
	<u>1,327</u>	<u>1,346</u>

(ii) Contract liabilities

Information about contract liabilities from contracts with customers disclosed as below:

	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000
Group		
Customer loyalty programme – unredeemed loyalty points	177	177
Advance received from customers	161	-
	<u>338</u>	<u>177</u>

Contract liabilities primarily pertain to redeemable points accorded to customers from their purchases with the Group under the Group's customer loyalty programme and advance received from customers for sale of products.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

6 SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services, and has two reportable operating segments as follows:

- 1) The Health Food Trade segment provides distributions and trading in health foods and supplements.
- 2) The Corporate and others segment includes general corporate income and expense items.

Business Segments	Health Food Trade		Corporate		Consolidated	
	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000
Revenue:						
External customers	1,327	1,346	-	-	1,327	1,346
Results:						
Depreciation of property, plant and equipment	20	29	-	-	20	29
Depreciation for right-of-use assets	289	328	-	-	289	328
Property, plant and equipment written off	-	5	-	-	-	5
Interest expenses	32	24	41	-	73	24
Loss before tax	(271)	(136)	(128)	(146)	(399)	(282)
Assets:						
Segment assets	4,228	2,882	344	208	4,572	3,090
Segment liabilities	(4,614)	(3,492)	(3,691)	(1,898)	(8,305)	(5,390)

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

6 SEGMENT INFORMATION (Cont'd)

Geographical information

Revenue and non-current assets information based on the geographical location of customers and assets respectively are as follows:

	Revenue		Non-current assets	
	3 Months Ended 30 Apr 2022	3 Months Ended 30 Apr 2021	As At 30 Apr 2022	As At 30 Apr 2021
	S\$'000	S\$'000	S\$'000	S\$'000
Singapore	1,327	1,346	2,370	1,364
	<u>1,327</u>	<u>1,346</u>	<u>2,370</u>	<u>1,364</u>

Non-current assets information presented above represent property, plant and equipment and right-of-use assets, and other receivables as presented in the statement of financial position.

7 LOSS BEFORE TAX

The following items have been included in arriving at the loss for the period:

	3 Months Ended 30 Apr 2022	3 Months Ended 30 Apr 2021
	S\$'000	S\$'000
Employee benefits expense	458	420
Depreciation for property, plant and equipment	20	29
Depreciation for right-of-use assets	289	328
Lease expenses not included in lease liabilities:		
- Variable lease expenses	23	73
Property, plant and equipment written off	-	5
Interest expenses	73	24
Gain on lease modification	-	(239)
Government grants	(12)	(42)
Rent concessions and rebate	-	(10)

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

8 RELATED PARTY TRANSACTIONS

Some of the Company's transactions and arrangements are with related parties and the effect of these on the basis determined between the parties is reflected in these financial statements.

	3 Months Ended 30 Apr 2022 S\$'000	3 Months Ended 30 Apr 2021 S\$'000
Compensation of key management personnel		
- Director of the Company	38	-
- Director of a subsidiary	38	26
	<u>76</u>	<u>26</u>
Interest on loan from controlling shareholder	4	-
	<u>4</u>	<u>-</u>

9 LOSS PER SHARE

Loss per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

	3 Months Ended 30 Apr 2022	3 Months Ended 30 Apr 2021
Loss per share (in SGD cents)		
- Basic ⁽¹⁾	(1.33)	(0.94)
- Fully diluted ⁽²⁾	(1.33)	(0.94)
	<u>(1.33)</u>	<u>(0.94)</u>

⁽¹⁾ Basic loss/ earnings per share ("EPS") is calculated on the Group's loss for the period divided by the weighted average number of ordinary shares in issue during the reporting period of 29,999,993 shares (30 Apr 2021: 29,999,993 shares).

⁽²⁾ As there are no dilutive potential ordinary shares issued and/or granted, the fully diluted EPS is the same as the basic EPS.

10 FINANCIAL INSTRUMENTS

	Group		Company	
	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000
Financial assets at amortised cost	1,505	1,020	1,844	59
Financial liabilities at amortised cost	7,742	6,459	2,739	877

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

11 PROPERTY, PLANT AND EQUIPMENT

Group	Plant and Machinery, Furniture and Vehicles S\$'000
Cost	
As at 1 Feb 2021	2,237
Additions	33
Disposal/written off	(282)
As at 31 Jan 2022	<u>1,988</u>
As at 1 Feb 2022	1,988
Additions	16
As at 30 Apr 2022	<u>2,004</u>
Accumulated depreciation	
As at 1 Feb 2021	1,721
Depreciation charge for the year	102
Disposal/written off	(74)
As at 31 Jan 2022	<u>1,749</u>
As at 1 Feb 2022	1,749
Depreciation charge for the year	20
As at 30 Apr 2022	<u>1,769</u>
Accumulated impairment loss	
As at 1 Feb 2021	286
Disposal/written off	(172)
Impairment loss	19
As at 31 Jan 2022	<u>133</u>
As at 1 Feb 2022	133
Impairment loss	-
As at 30 Apr 2022	<u>133</u>
Net carrying amount	
As at 31 Jan 2022	<u>106</u>
As at 30 Apr 2022	<u>102</u>

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

12 RIGHT-OF-USE ASSETS

Group	Office Premise and Retail Outlets S\$'000
Cost	
As at 1 Feb 2021	5,933
Lease modification	1,745
Early termination	(674)
Expiry	(219)
As at 31 Jan 2022	<u>6,785</u>
As at 1 Feb 2022	6,785
Lease modification	652
As at 30 Apr 2022	<u>7,437</u>
Accumulated depreciation and impairment loss	
As at 1 Feb 2021	4,723
Charge	1,209
Impairment loss	130
Early termination	(674)
Expiry	(219)
As at 31 Jan 2022	<u>5,169</u>
As at 1 Feb 2022	5,169
Charge	289
As at 30 Apr 2022	<u>5,458</u>
Net carrying amount	
As at 31 Jan 2022	<u>1,616</u>
As at 30 Apr 2022	<u>1,979</u>

13 INVENTORIES

	Group		Company	
	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000	30 Apr 2022 S\$'000	31 Jan 2022 S\$'000
Health foods and supplements:				
Raw materials	277	129	-	-
Finished goods	363	463	-	-
Goods in transit	-	26	-	-
	<u>640</u>	<u>618</u>	<u>-</u>	<u>-</u>

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

14 TRADE AND OTHER RECEIVABLES

	Group		Company	
	30 Apr 2022	31 Jan 2022	30 Apr 2022	31 Jan 2022
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Trade receivables	148	93	-	-
			-	-
Other receivables				
- Rental deposits	171	155	-	-
- Deferred lease payments	18	15	-	-
- Prepayments	278	6	2	2
- Advances to former directors	59	59	59	59
- Amount due from subsidiaries	-	-	1,552	-
- Sundry receivables	738	730	-	-
- Advance payment to suppliers	286	80	-	-
	1,550	1,045	1,613	61
Impairment loss allowance	(723)	(723)	-	-
	827	322	1,613	61
<u>Non-current</u>				
- Rental deposits	271	232	-	-
- Deferred lease payments	18	12	-	-
	289	244	-	-

Advances to former directors of \$59,000 refer to payments made by the former management to three former independent directors of the Company purportedly for their directors' fees in respect of the financial year ended 31 January 2020. The payment of such purported directors' fees is strictly subject to the approval of the shareholders of the Company at a general meeting under the Companies Act 1967 and the constitution of the Company. As the resolution in respect of the payment of such directors' fees was voted by the shareholders at the Annual General Meeting held on 31 December 2021, the Company is in the midst of seeking recovery of the sums paid-out from these former Independent Directors, as well as legal advice in connection with such recovery.

15 LOANS AND BORROWINGS

	Group		Company	
	30 Apr 2022	31 Jan 2022	30 Apr 2022	31 Jan 2022
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Term loans	744	864	-	-

The outstanding loan as at reporting date is unsecured, bears interest between 1.56% and 2.71% per annum.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

16 TRADE AND OTHER PAYABLES

	Group		Company	
	30 Apr 2022	31 Jan 2022	30 Apr 2022	31 Jan 2022
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Trade payables	709	746	-	-
Other payables				
Third parties	858	1,138	330	467
Accrued expenses	523	670	120	229
Loan from ultimate holding company (Note 2.2)	315	311	-	-
Amount due to subsidiaries	-	-	-	181
	<u>1,696</u>	<u>2,119</u>	<u>450</u>	<u>877</u>
<u>Non-current</u>				
Other payables				
Loan from Investor (Note 2.2)	2,289	716	2,289	-

Included in trade payables and accrued expenses are balances owing to I-Nitra Consulting Limited (“I-Nitra”) of S\$435,000 (31 Jan 2022: \$425,000) and S\$149,000 (31 Jan 2022: S\$149,000) respectively. The outstanding balance is attributable to the purchase of some honey products from I-Nitra that were previously sold by NF to another party as well as amounts due to I-Nitra pursuant to consignment arrangements between I-Nitra (as consignor) and NF (as consignee) upon the sale of the consigned goods by the latter. The purchase transactions and consignment arrangements ostensibly took place during 2019 on the previous management’s watch and were subject matter of investigation by the special auditors pursuant to a notice of compliance issued by the Singapore Exchange Regulation in March 2019. While these transactions involving I-Nitra were at first blush redolent of round-tripping, the special auditors had emphatically concluded that they “did not find any conclusive evidence of round-tripping”. Accordingly, and out of accounting prudence, the incumbent management has not derecognised the liability as at reporting date.

Loan from ultimate holding company is unsecured, bears interest at 5% per annum and is repayable in November 2022.

Loan from Investor is unsecured, bears interest at 12% per annum and is repayable in December 2023.

Amount due to subsidiaries is non-trade in nature, unsecured, non-interest bearing and repayment on demand.

CAMSING HEALTHCARE LIMITED
NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

17 LEASE LIABILITIES

	Group		Company	
	30 Apr 2022	31 Jan 2022	30 Apr 2022	31 Jan 2022
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Current</u>				
Lease liabilities	1,182	1,126	-	-
<u>Non-current</u>				
Lease liabilities	1,122	888	-	-
Total lease liabilities	<u>2,304</u>	<u>2,014</u>	<u>-</u>	<u>-</u>

The Group have entered into lease agreement for retail stores and office premises. These non-cancellable leases have lease terms of between 1 and 3 years. The effective interest rate of lease liabilities is 5.25%.

18 SHARE CAPITAL

	Group and Company			
	30 Apr 2022		31 Jan 2022	
	Number of		Number of	
	ordinary	S\$'000	ordinary	S\$'000
	shares		shares	
<u>Issued and fully paid:</u>				
At beginning and end of year	<u>29,999,993</u>	<u>14,250</u>	<u>29,999,993</u>	<u>14,250</u>

The Company has one class of ordinary shares which carry one vote per share. The ordinary shares have no par value and carry a right to dividends as and when declared by the Company.

19 NET ASSET VALUE

Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the (a) currently period reported on and (b) immediately preceding financial year.

	Group		Company	
	30 Apr 2022	31 Jan 2022	30 Apr 2022	31 Jan 2022
	Cents	Cents	Cents	Cents
Net (liabilities)/assets per ordinary share based on existing issued share capital as at the end of period/year	<u>(12.43)</u>	<u>(11.10)</u>	<u>0.02</u>	<u>0.28</u>

Net (liability) / asset value per ordinary share was based on 29,999,993 (31 Jan 2022: 29,999,993) ordinary shares outstanding as at end of the reporting period.

20 SUBSEQUENT EVENTS

There are no known significant subsequent events which have led to adjustment to this set of interim financial statements.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2

- 21A Details of any changes in the company’s share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.**

There have been no changes in the Company’s share capital since the end of the previous period reported.

For the avoidance of doubt, the Company has no outstanding convertible securities as at: (i) the end of the current financial period reported on; and (ii) the corresponding period of the immediately preceding financial year.

- 21B The total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.**

	30 Apr 2022	31 Jan 2022
	Number of ordinary shares	Number of ordinary shares
Number of issued shares	<u>29,999,993</u>	<u>29,999,993</u>

- 21C A statement showing all sales, transfers, disposals, cancellation and/or use of treasury shares as at the end of the current financial period reported on.**

The Company does not have any treasury shares.

- 22 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

The figures have not been audited nor reviewed by the auditors.

- 23 Where the figures have been audited or reviewed, the auditors’ report (including any qualifications or emphasis of matter).**

Not applicable.

CAMSING HEALTHCARE LIMITED

24 Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:-

- (a) Updates on the efforts taken to resolve each outstanding audit issue**
- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed**

The auditors have rendered an “except for” qualified opinion on the latest audited financial statements for the financial year ended 31 January 2022 (“FY2022”) via their report dated 23 August 2022. The basis for qualified opinion is as follows:

Opening balances

The auditors’ reservations on certain opening balances for FY2021 arose from their previous audits for FY2019 and FY2020 when they were first appointed in November 2021 to undertake those audits after the release of the special audit report dated 1 September 2020 and that they were not given access to any relevant and substantive working papers relating to FY2018 by the predecessor auditors. More specifically, these opening balances for FY2021 refer to balances of inventories, investment in Nature’s Farm, amount owing to I-Nitra and accumulated losses account as at 1 February 2020. Nonetheless, as the auditors have satisfied themselves with the closing balances of these balance sheet items as at 31 January 2021, the auditors would also be satisfied with these opening balances in respect of the FY2022 audit except for the amount owing to I-Nitra as more fully described below.

Consignment arrangements with I-Nitra

The auditors have expressed reservations on the commercial substance or business rationale of the consignment arrangements given that such arrangements were initially highlighted in the special audit report as potentially round-tripping. However, the special auditors had eventually found and concluded in their report that there was no round-tripping involved. The Company has duly disclosed its position regarding the consignment arrangements (including the purported amounts owing to I-Nitra) and the pertinent findings and conclusion of the special auditors in Note 9 to the FY2022 audited financial statements and in paragraph 16 of this Announcement.

The Board confirms that the impact of all outstanding audit issues on this Announcement have been adequately disclosed herein.

- 25 **A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the revenue, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets and liabilities of the group during current financial period reported on.**

Review of Results

The Group's revenue of S\$1,327,000 for the three months ended 30 April 2022 ("Q1FY2023") were generated from local retail sales. The decrease in the revenue by S\$19,000 compared to the three months ended 30 April 2021 ("Q1FY2022") was mainly due to reduced demand for products during the period under review.

The Group recorded S\$36,000 other income in Q1FY2023, compared to S\$315,000 in Q1FY2022. Other income comprises mainly government grant and product display fee in Q1FY2023.

Marketing and distribution expenses decreased by S\$88,000 or 9% from S\$1,007,000 in Q1FY2022 to S\$919,000 in Q1FY2023. The decrease was mainly due to decrease in marketing expenses and depreciation for right-of-use assets.

Administrative and other operating expenses decreased by S\$81,000 or 29% from S\$280,000 in Q1FY2022 to S\$199,000 in Q1FY2023, primarily due to higher professional fees incurred in Q1FY2022.

The higher finance costs were due mainly to the interest on loans from the Investor and ultimate holding company being recognised in Q1FY2023; there was no such loans in Q1FY2022.

The Group recorded a loss before tax of S\$399,000 in Q1FY2023 compared to a loss before tax of S\$282,000 in Q1FY2022, which was mainly attributable to less other income during the period under review.

Review of Statement of Financial Position

The Group's non-current assets stood at S\$2,370,000 as of 30 April 2022, compared to S\$1,966,000 as of 31 January 2022, and comprised property, plant and equipment, right-of-use assets and other receivables. The increase of S\$404,000 was mainly attributable to an increase in right-of-use assets due to the renewal of lease agreements, offset by the depreciation of such assets during Q1FY2023.

The current assets stood at S\$2,202,000 as of 30 April 2022, compared to S\$1,546,000 as of 31 January 2022. Overall, the increase of S\$656,000 in current assets was mainly due to the increase of S\$560,000 in trade and other receivables and S\$83,000 in cash at bank.

The net decrease of S\$363,000 in current liabilities was mainly due to decrease of S\$460,000 in trade and other payables, S\$120,000 in loans and borrowings, offset by increase of S\$161,000 in contract liabilities. The decrease in loans and borrowings are mainly due to repayments during Q1FY2023.

The increase of S\$1,822,000 in non-current liabilities was mainly due to increase in loan from the Investor and lease liabilities.

Overall, the Group's net liabilities stood at S\$3,733,000 as of 30 April 2022, compared to S\$3,334,000 as of 31 January 2022.

Review of Cash Flow

The Group recorded net cash flows used in operating activities of S\$923,000 in Q1FY2023, as compared to net cash flows generated from operating activities of S\$419,000 in Q1FY2022. The decrease was mainly attributable to operating losses incurred, cash outflow from receivables and payables, offset by cash inflow from contract liabilities.

The net cash flows used in investing activities of S\$16,000 in Q1FY2023 was due to purchase of property, plant, and equipment.

The net cash flows generated from financing activities of S\$1,022,000 in Q1FY2023 was mainly attributable to the Group receiving a loan amounting to S\$1,532,000 from the investor during the period under review.

On account of the above, the Group's cash and cash equivalents in the consolidated statement of cashflows comprise cash and bank balances of S\$557,000 as of 30 April 2022.

26 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, the issuer must explain any variance between the forecast or prospect statement and the actual results

No forecast or prospect statement has been previously disclosed to shareholders.

27 Commentary at the date of the announcement of the competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

With global supply chains continuing to be disrupted and inflation rising, the Group anticipates slower economic growth in the coming quarters, which may adversely impact consumer sentiment. Nonetheless, the Group will continue to execute its cores strategies in developing new products, expanding into new sales channels and apply prudent cost management measures.

The Group notes that a sizable portion of NF's revenue is still generated by walk-in customers to its retail outlets. As COVID-19 has greatly increased the prevalence and acceptance of e-commerce, the Group will continue augmenting its online presence and platforms. The Group has also undertaken successful business-to-business ("B2B") collaborations, and intends to continuously seek out other reputable partners in complementary industries.

Trading in the shares of the Company has been suspended since 1 April 2019. The Group notes that great strides have been taken since to resolve its regulatory irregularities and address other areas of concern which had contributed to its trading suspension. For example, the Company announced completion of its internal control review on 8 August 2022, and that the Company has addressed and implemented a significant majority of the recommendations of the review report. Shareholders may refer to the Company's announcement dated 8 August 2022 for more details. The Company aims to ride on this momentum and submit a proposal for the resumption in the trading of its shares in the near future.

28 Dividend

(a) Current Financial Period Reported On

Any dividend recommended for the current financial period reported on?

No.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

No.

(c) Date Payable

Not applicable.

(d) Books Closure Date

Not applicable.

29 If no dividend has been declared/recommended, a statement to that effect

No dividend has been declared or recommended for the current financial period as the Company and/or the Group recorded net losses for the financial period under review.

30 If the Group has obtained a general mandate from shareholders for Interested Person Transactions (“IPTs”), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

During the financial period under review, the Group did not have a general mandate pursuant to Rule 920 of the SGX-ST Listing Manual. There were no Interested Person Transactions exceeding \$100,000 in aggregate value for the current financial period.¹

31 Report of persons occupying managerial positions who are related to a director, chief executive officer or substantial shareholder Pursuant to Rule 704 (13)

The Board confirms that, to the best of its knowledge, as of the date hereof, none of the persons occupying managerial positions in the Company or any of its principal subsidiaries is a relative of a Director, Chief Executive Officer or Substantial Shareholder of the Company.

32 Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1).

Pursuant to Rule 720(1) of the Listing Manual, the Company has procured undertakings from all its directors and executive officers.

¹ In arriving at the conclusion, the Board wishes to state for the record that it did not include the transactions with Caring Global Health Management (Beijing) Co., Ltd, Global Biotech Medical Inc., Limited, I-Nitra Consulting Limited as interested person transactions as RSM did not conclude these three companies as interested persons after their extensive investigation from April 2019 to September 2020. Please refer to the ES-SAR released by Company on 1 September 2020 via SGXNet.

CAMSING HEALTHCARE LIMITED

33 Negative confirmation by the Board pursuant to Rule 705(5)

On behalf of the board of directors of the Company, we hereby confirm to the best of our knowledge that nothing has come to the attention of the Board which may render the unaudited financial statements and dividend announcement for the three months ended 30 April 2022 to be false or misleading in any material aspect.

BY ORDER OF THE BOARD

LIU HUI
Executive Director
28 September 2022